Vaccines

Moderna has cleared a major regulatory milestone in Europe after the EMA’s CHMP recommended approval of mRNA-1083 (mCOMBRIAX), the world’s first combined influenza and COVID-19 vaccine for adults aged 50 and older.

This week, read about the newest measles update, a clinician's insights on treating the respiratory disease, as well as the latest HIV therapeutic data coming from the CROI conference.

This week, read about the changes to the pediatric vaccine schedule, RSV protection, the FDA reversing course on Moderna's influenza vaccine, and more.

The latest CDC numbers show a 7.9% increase of measles cases from week-to-week. While the number of new measles cases are down from the previous week, there are more states and outbreaks circulating throughout the US.

In this month's column, we look at the recommendation changes made by the CDC to the pediatric vaccine schedule, as well as the American Academy of Pediatrics' response with its own vaccine schedule.

The federal agency is bringing over NIH Director Jayanta "Jay" Bhattacharya, MD, PhD, to fill the position.

Invivyd has aligned with the FDA on the design of a phase 3 trial evaluating the safety and immunology of the company's monoclonal antibody, VYD2311, vs mRNA COVID vaccines and in co-administration.

New real-world evidence presented by GSK shows its RSV vaccine, Arexvy, was associated with substantial reductions in RSV-related hospitalizations and serious cardiovascular and respiratory complications among older adults.

After initially refusing to review Moderna’s investigational mRNA-based seasonal influenza vaccine, the company communicated with the FDA on a revised proposal to seek approval and the federal agency will now review the product. The vaccine's PDUFA decision date is August 5, 2026.

Findings from a real-world population study from Spain show that universal infant immunization with Beyfortus significantly reduced RSV-related hospitalizations not only in the first RSV season but also into the second year of life.

This week, listen in on commentary around the potential removal of the COVID-19 vaccine from the US market, read about FDA's refusal to review Moderna's influenza vaccine, CDC's investigation on invasive E coli, and more.

The latest CDC numbers show a nearly 25% increase of measles cases from week-to-week. This marks 2 weeks in a row with a nearly identical increase of cases by percentage, and there are now 5 outbreaks circulating throughout the US.

New amicus brief from scholars and professional organizations including the American Thoracic Society and American Academy of Allergy, Asthma & Immunology supports AAP lawsuit against HHS changes to pediatric vaccine schedule.

The FDA declined to review Moderna’s mRNA flu vaccine application for its mRNA-1010 product, and based its decision on it choice of comparator in a phase 3 trial, despite the absence of safety or efficacy concerns and prior FDA agreement on the study design. Moderna requested a meeting to understand the path forward with the vaccine.

This week, listen in on commentary around the ongoing measles outbreak, read our new Antibiotics Deconstructed column on IV fosfomycin, review data on metformin preventing long COVID, insights on diagnostic stewardship, and more.

The latest CDC numbers show a significant increase week-to-week.

The Centers for Disease Control and Prevention (CDC) provided its latest figures today on the confirmed number of cases in the US.

The American Academy of Pediatrics (AAP) has published its 2026 immunization schedule, reaffirming routine vaccination to protect children and adolescents against 18 preventable diseases.

Infectious disease pediatrician Sharon Nachman, MD, discusses the vaccine data the federal agency disclosed in the recent letter they sent to the manufacturers.

The workgroup is examining the vaccine’s schedule including the age it is administered, dosage, and the safety and efficacy of the vaccines.

Kirk Milhoan, MD, PhD, said vaccine choice is the most important element to the public even with the possibility of people contracting this disease or others when given the right to opt out of vaccination.

Although the declared COVID-19 pandemic public health emergency has passed, the CDC reports continued high numbers of illnesses, medical visits, hospitalizations and deaths.

Valneva has voluntarily withdrawn its US regulatory applications for its chikungunya vaccine, IXCHIQ, after the FDA suspended the license and placed the program on clinical hold pending investigation of a newly reported serious adverse event.

Evidence supporting the second of two licensed pentavalent meningococcal vaccines as an alternative to separate quadrivalent (ACWY) and serogroup B (MenB) vaccines is described and qualified in a recent MMWR.

Infectious disease pediatrician Sharon Nachman, MD, offers insights on the incidence trends among teens, and what severe disease complications look like for young children.